Bio-Techne TECH Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Bio-Techne’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Techne's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Techne's additional paid-in capital?
- Bio-Techne (TECH) reported additional paid-in capital of $1.01B in Q1 2026.
- How has Bio-Techne's additional paid-in capital changed year-over-year?
- Bio-Techne's additional paid-in capital increased by 11.4% year-over-year, from $902.12M to $1.01B.
- What is the long-term trend for Bio-Techne's additional paid-in capital?
- Over 4 years (2021 to 2025), Bio-Techne's additional paid-in capital has grown at a 14.3% compound annual growth rate (CAGR), from $534.41M to $911.09M.
- What does additional paid-in capital mean?
- The amount of capital received from shareholders above the par value of the stock.
- How do you interpret additional paid-in capital?
- Increases indicate equity-based financing or the exercise of employee stock options.
- How does additional paid-in capital compare across companies?
- Common in growth-oriented life science companies that utilize equity for compensation and funding.